## Francesco Gaudio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6136363/publications.pdf

Version: 2024-02-01

623188 610482 38 634 14 24 citations g-index h-index papers 39 39 39 998 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood, 2011, 118, 3419-3425.	0.6	123
2	High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab. Acta Haematologica, 2011, 126, 44-51.	0.7	48
3	Microvascular density, CD68 and tryptase expression in human Diffuse Large B-Cell Lymphoma. Leukemia Research, 2014, 38, 1374-1377.	0.4	44
4	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood, 2014, 124, 3029-3031.	0.6	40
5	Recovery of CMV-Specific CD8+ T Cells and Tregs after Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 550-557.	2.0	31
6	Inflammatory Cells in Diffuse Large B Cell Lymphoma. Journal of Clinical Medicine, 2020, 9, 2418.	1.0	29
7	CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 887-893.	2.0	27
8	Bone Involvement in Hodgkin's Lymphoma: Clinical Features and Outcome. Acta Haematologica, 2018, 140, 178-182.	0.7	21
9	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. Oncotarget, 2017, 8, 91703-91710.	0.8	21
10	Serological response following BNT162b2 antiâ€SARSâ€CoVâ€2 mRNA vaccination in haematopoietic stem cell transplantation patients. British Journal of Haematology, 2022, 196, 928-931.	1.2	20
11	STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas. Leukemia and Lymphoma, 2020, 61, 567-574.	0.6	19
12	Outcome of Allogeneic Peripheral Blood Stem Cell Transplantation by Donor Graft CD3+/Tregs Ratio: A Single-Center Experience. Biology of Blood and Marrow Transplantation, 2013, 19, 495-499.	2.0	18
13	Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas. Advances in Hematology, 2011, 2011, 1-6.	0.6	17
14	T cells, mast cells and microvascular density in diffuse large B cell lymphoma. Clinical and Experimental Medicine, 2016, 16, 301-306.	1.9	17
15	STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma. Translational Oncology, 2019, 12, 545-549.	1.7	14
16	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leukemia Research, 2014, 38, 1446-1450.	0.4	13
17	Risk of lymphoma subtypes by occupational exposure in Southern Italy. Journal of Occupational Medicine and Toxicology, 2017, 12, 31.	0.9	13
18	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica, 2017, 102, 1931-1935.	1.7	11

#	Article	lF	Citations
19	Pregnancy rate and outcome of pregnancies in long-term survivors of Hodgkin's lymphoma. Annals of Hematology, 2019, 98, 1947-1952.	0.8	11
20	Lenalidomide in Pretreated Patients with Diffuse Large Bâ€Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. Oncologist, 2019, 24, 1246-1252.	1.9	10
21	Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 35-40.	0.2	10
22	Correlation between circulating blood and microenvironment T lymphocytes in diffuse large B-cell lymphomas. Journal of Clinical Pathology, 2022, 75, 493-497.	1.0	10
23	Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naÃ-ve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). Annals of Hematology, 2018, 97, 1817-1824.	0.8	9
24	Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. Annals of Hematology, 2018, 97, 663-668.	0.8	8
25	Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients. Annals of Hematology, 2019, 98, 1449-1455.	0.8	8
26	Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e506-e512.	0.2	7
27	Extralymphatic Disease Is an Independent Prognostic Factor in Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e261-e266.	0.2	6
28	Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma. Leukemia and Lymphoma, 2014, 55, 1596-1601.	0.6	5
29	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. Leukemia and Lymphoma, 2016, 57, 2370-2374.	0.6	5
30	Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. Journal of Clinical Medicine, 2022, 11, 1257.	1.0	5
31	Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma. Clinical and Experimental Medicine, 2021, 21, 573-578.	1.9	4
32	CT-guided needle biopsy performed with modified coaxial technique in patients with refractory or recurrent lymphomas. Annals of Hematology, 2014, 93, 1559-1564.	0.8	3
33	The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells. Diagnostics, 2022, 12, 573.	1.3	3
34	In male Hodgkin lymphoma patients, impaired fertility may be improved by nonâ€gonadotoxic therapy. British Journal of Haematology, 2022, 196, 110-115.	1.2	2
35	INDOLENT LYMPHOPROLIFERATIVE T-CELL DISORDERS ASSOCIATED WITH GASTROINTESTINAL DISEASE: DIAGNOSTIC CHALLENGES AND OUTCOMES. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	2
36	Computed tomography-guided needle biopsy performed with modified coaxial technique in patients with suspected lymphoma. Leukemia and Lymphoma, 2014, 55, 1949-1951.	0.6	0

#	Article	IF	CITATIONS
37	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e321-e323.	0.2	O
38	Relapsing/refractory HL after autotransplantation: which treatment?. Acta Biomedica, 2020, 91, 30-40.	0.2	0